Clinical Trial Update: Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a polarized dendritic cell (aDC1)-based treatment in combination with Interferon Alpha-2, Rintatolimod, and Celecoxib for HLA-A2+ ref…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Celecoxib (Celecoxib)
• Interferon Alpha-2 (Interferon alfa-2)
• Polarized Dendritic Cell (aDC1) Based Treatment
• Rintatolimod (rintatolimod)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: HLA-A2 Positive Cells Present, Refractory Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2026-02-25